Feedback / Questions
ATL-201 - Atalanta Therapeutics
ATL-101 - Atalanta Therapeutics
https://www.businesswire.com/news/home/20250128583264/en/Atalanta-Therapeutics-Closes-Oversubscribed-97-Million-Series-B-Financing-to-Advance-Two-RNAi-Therapies-for-CNS-Diseases-to-Clinical-Trials
 
Jan 28, 2025
 
SHARE THIS
  • Print
  • Email
  • More sharing
    Reddit
    StumbleUpon
    Delicious